Adalimumab commissioning intentions

This document builds upon NHS England’s commissioning intentions for biological medicines published in September 2017. It sets out the tendering strategy for adalimumab in particular, as well as provides guidance for commissioners and providers on the issue.

AdalimumabNewsRMOC recommendations and resources

Attachments